Search

Search Constraints

You searched for: Author/Creator Qiu, Lugui

Search Results

21. Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Issue 9 (13th September 2022)

22. Phase 3 study of subcutaneous bortezomib, thalidomide, and prednisolone consolidation after subcutaneous bortezomib-based induction and autologous stem cell transplantation in patients with previously untreated multiple myeloma: the VCAT study. Issue 9 (29th July 2019)

23. Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma. Issue 1 (December 2016)

24. Phase II open‐label study of recombinant circularly permuted TRAIL as a single‐agent treatment for relapsed or refractory multiple myeloma. Issue 1 (8th September 2016)

25. Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. (10th February 2020)

26. Prognostic value of high serum lactate dehydrogenase in plasma cell dyscrasias: a re-evaluation in the context of cytogenetic aberration data. Issue 11 (November 2013)

27. Prominent immune signatures of T cells are specifically associated with indolent B‐cell lymphoproliferative disorders and predict prognosis. Issue 1 (22nd January 2020)

28. Pseudomonas aeruginosa bloodstream infection in patients with hematological diseases: Clinical outcomes and prediction model of multidrug-resistant infections. Issue 1 (January 2023)

29. Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy. (15th July 2020)

30. Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial. Issue 1 (January 2019)